Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Appili Therapeutics Inc T.APLI

Alternate Symbol(s):  APLIF

Healthcare
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical... see more

Recent & Breaking News (TSX:APLI)

Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.

GlobeNewswire 3 days ago

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025

GlobeNewswire 8 days ago

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Business Wire November 8, 2024

Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Business Wire November 7, 2024

Appili Therapeutics Announces Results of Special Meeting of Shareholders

GlobeNewswire November 6, 2024

Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem

Business Wire November 6, 2024

The top TSX healthcare stocks under $1

Jonathon Brown November 5, 2024

Aditxt's Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Business Wire October 31, 2024

Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

GlobeNewswire October 31, 2024

Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time

Business Wire October 30, 2024

Sylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives

Business Wire October 29, 2024

Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem

Business Wire October 28, 2024

Appili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek(TM) 2024

GlobeNewswire October 17, 2024

Appili Therapeutics - Press Release Correction

GlobeNewswire October 10, 2024

Aditxt's Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili's Shareholder Approval

Business Wire October 10, 2024

Appili Therapeutics Announces Mailing of the Management Information Circular in Connection with the Special Meeting of Shareholders

GlobeNewswire October 10, 2024

Aditxt Delivers Shareholder Update and 2024 Year-End Plan

Business Wire October 3, 2024

Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders

GlobeNewswire September 17, 2024

Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024

Business Wire August 29, 2024

Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics

Business Wire August 21, 2024